Figure 7
From: PRMT5 is a therapeutic target in choroidal neovascularization
Hypothetical model. PRMT5 methylates and activates NF-κB. This results in the induction of NF-κB downstream genes, including cytokines, angiogenesis factors, chemokines, and antiapoptotic genes, whose functions are critical for inflammation and angiogenesis. Thus, using PR5-LL-CM01 to block the activity of PRMT5 will inhibit neovascularization-associated eye diseases.
